Drugs / 177Lu-FF58
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05977322 | Oct 2023 → Dec 2024 | gastroesophageal adenocarcinoma, glioblastoma, pancreatic ductal adenocarcinoma | Novartis Pharmaceuticals | Terminated | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 177Lu-FF58 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05977322 ↗ |